Articles with the topic: clinical-trial

Sad news from the SIGNAL study: pepinemab does not influence HD symptoms

Sad news from the SIGNAL study: pepinemab does not influence HD symptoms

The SIGNAL study did not meet its key clinical goals for #HuntingtonsDisease to slow or improve HD symptoms, but the results are still informative for the HD community and other fields.

Dr Jeff CarrollSeptember 23, 2020

HD Young Adult Study defines the sweet spot: symptom-free with measurable changes

HD Young Adult Study defines the sweet spot: symptom-free with measurable changes

We know that HD-related changes can occur many years before symptom onset, but how early do those changes begin? A team of researchers set out to determine that with a new comprehensive study in pre-manifest HD young adults.

Dr Sarah HernandezMay 27, 2020

What does COVID-19 mean for Huntington’s disease families and HD research?

What does COVID-19 mean for Huntington’s disease families and HD research?

COVID-19 update: what does it mean for HD families, how does it impact HD research, and how has it changed the way science works?

Dr Sarah Hernandez and Dr Ed WildApril 06, 2020

Unpacking Wave's PRECISION-HD2 huntingtin-lowering trial announcement

Unpacking Wave's PRECISION-HD2 huntingtin-lowering trial announcement

Wave Life Sciences announces that its antisense drug WVE-120102 has lowered mutant huntingtin protein in cerebrospinal fluid, but investors seem disappointed. Rather confusing – what do we know for sure?

Dr Jeff CarrollJanuary 03, 2020

Details emerge of first Huntington’s disease gene therapy clinical trial

Details emerge of first Huntington’s disease gene therapy clinical trial

UniQure announces key details of its planned trial to assess the safety and ability of AMT-130 gene therapy to lower the problematic huntingtin protein using a ‘single-shot’ virus delivery system.

Dr Anna PfalzerJuly 17, 2019

Advances on many fronts in the battle against the protein that causes Huntington's disease

Advances on many fronts in the battle against the protein that causes Huntington's disease

This fall sees exciting announcements from a number of companies focused on novel Huntingtin Lowering technologies, including Wave, PTC and Voyager

Dr Jeff CarrollDecember 04, 2018

Disappointing news from LEGATO-HD trial of laquinimod in Huntington's disease

Disappointing news from LEGATO-HD trial of laquinimod in Huntington's disease

The LEGATO-HD trial of laquinimod did not slow progression of Huntington's disease. Here's the lowdown.

Dr Jeff CarrollAugust 02, 2018

Success! ASO drug reduces levels of mutant protein in Huntington's disease patients

Success! ASO drug reduces levels of mutant protein in Huntington's disease patients

Amazing news from Ionis and Roche! HTTRx drug successfully lowers harmful huntingtin protein in spinal fluid

Dr Jeff CarrollDecember 11, 2017

A new way of thinking about trials to prevent Huntington's disease

A new way of thinking about trials to prevent Huntington's disease

Can we test drugs to delay or prevent the onset of Huntington's disease? New research suggests it's possible

Dr Jeff CarrollOctober 27, 2017